Sex-Related Differences in Impact on Safety of Pharmacogenetic Profile for Colon Cancer Patients Treated with FOLFOX-4 or XELOX Adjuvant Chemotherapy

Polymorphisms contribute to inter-individual differences and show a promising predictive role for chemotherapy-related toxicity in colon cancer (CC). TOSCA is a multicentre, randomized, non-inferiority, phase III study conducted in high-risk stage II/stage III CC patients treated with 6 vs 3 months...

Full description

Saved in:
Bibliographic Details
Published in:Sci Rep
Main Authors: Ruzzo, Annamaria, Graziano, Francesco, Galli, Francesca, Galli, Fabio, Rulli, Eliana, Lonardi, Sara, Ronzoni, Monica, Massidda, Bruno, Zagonel, Vittorina, Pella, Nicoletta, Mucciarini, Claudia, Labianca, Roberto, Ionta, Maria Teresa, Bagaloni, Irene, Veltri, Enzo, Sozzi, Pietro, Barni, Sandro, Ricci, Vincenzo, Foltran, Luisa, Nicolini, Mario, Biondi, Edoardo, Bramati, Annalisa, Turci, Daniele, Lazzarelli, Silvia, Verusio, Claudio, Bergamo, Francesca, Sobrero, Alberto, Frontini, Luciano, Magnani, Mauro
Format: Artigo
Language:Inglês
Published: Nature Publishing Group UK 2019
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC6687727/
https://ncbi.nlm.nih.gov/pubmed/31395900
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-019-47627-1
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items